Drug class

Antiviral-HIV Cytidine Analogue Nucleoside RT Inhibitors

Antiviral-HIV cytidine analogue nucleoside reverse transcriptase inhibitors (NRTIs) are a structural subcategory of antiretroviral agents, most prominently represented by lamivudine and emtricitabine. Read more about Antiviral-HIV Cytidine Analogue Nucleoside RT Inhibitors

77 drugs in this class 36 manufacturers

Advertisement

Drugs in Antiviral-HIV Cytidine Analogue Nucleoside RT Inhibitors

Showing 37–45 of 77 drugs

Filter & compare in the drug finder → Opens the drug finder with Antiviral-HIV Cytidine Analogue Nucleoside RT Inhibitors preselected. Add indication or manufacturer filters there.

About Antiviral-HIV Cytidine Analogue Nucleoside RT Inhibitors.

Antiviral-HIV cytidine analogue nucleoside reverse transcriptase inhibitors (NRTIs) are a structural subcategory of antiretroviral agents, most prominently represented by lamivudine and emtricitabine.

These agents mimic the endogenous pyrimidine nucleoside cytidine and, following intracellular phosphorylation into active triphosphate metabolites, compete with deoxycytidine triphosphate for incorporation into nascent viral DNA by HIV reverse transcriptase.

Because they lack a 3'-hydroxyl group, their incorporation causes premature viral DNA chain termination and prevents replication.

They serve as foundational backbone components in combination antiretroviral therapy for the management and prevention of human immunodeficiency virus type 1 (HIV-1) infection, and frequently possess concurrent therapeutic activity against hepatitis B virus (HBV) infection.